Report published June 10, 2026
The SMID Point: Citi Market Analysis and Sector Insights (June 2026)
Citi · June 10, 2026
This report provides research updates on various companies including Blackstone Digital Infrastructure, PTC Therapeutics, Seaport Therapeutics, and Shattuck Labs, alongside industry commentary from the ADA 2026 conference.
Read the remaining 4 pages
Finvaulta summarizes Citi's analysis. Attribute opinions, forecasts, time-sensitive values, and chronology to the issuer and report date; do not treat this page as an independent verification or a current market-data source.
Key Takeaways
- 1.Citi initiated coverage on Blackstone Digital Infrastructure Trust (BXDC) with a Neutral rating, citing valuation concerns despite favorable industry trends.
- 2.Lilly's retatrutide data at ADA 2026 demonstrated compelling efficacy (>30% weight loss) for obesity, suggesting broader adoption potential.
- 3.Seaport Therapeutics (SPTX) data supports advancement of GlyphAgo into two phase 2 trials, with safety and efficacy milestones expected through 2028.
Table of Contents
- Company
- Industry
Report data
Bull/Bear: Seaport Therapeutics Inc
| Metric | Estimate | Context |
|---|---|---|
| Weight loss efficacy | 30% | Lilly's retatrutide performance |
Reports in this series
The SMID Point is shown in chronological order through this edition, published on June 10, 2026.
Part of the The SMID Point series — view all 7 editions
Looking for the latest edition? Citi The SMID Point Tuesday, 30 June 2026 (Jun 30, 2026)
Access the full report
And others from the leading tier 1 banks.
Free account: read previews and a daily allowance of full reports. Pro removes the daily limit.